Phillip Minar, MD, MS
- Medical Director, Shubert-Martin Inflammatory Bowel Disease Center
- Program Director, Advanced Pediatric IBD Fellowship Training
- Associate Professor, UC Department of Pediatrics
- phillip.minar@cchmc.org
- Board Certified
About
BA: Duquesne University, Pittsburgh, PA.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH.
MD: Medical College of Wisconsin, Milwaukee, WI.
Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.
Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: General Pediatrics; Pediatric Gastroenterology.
Interests
Pediatric inflammatory bowel disease; evidence-based care for children and young adults with IBD; sustained, prednisone-free clinical remission
Services and Specialties
Interests
Application of personalized medicine in the care of children and young adults with IBD through the discovery of surrogate biomarkers of intestinal inflammation; sensitive and specific pharmacodynamic biomarker, neutrophil CD64; innovative pharmacokinetic dosing platform, RoadMAB; personalized dosing of biologic therapies for patients with IBD; novel method to dose infliximab (guided by RoadMAB) from the start of treatment and throughout the maintenance phase to assess both the effectiveness and safety of model-informed precision dosing.
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Circulating and Magnetic Resonance Imaging Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease. Inflammatory Bowel Diseases. 2025; 31:1380-1391.
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2025; 120:1076-1086.
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2025; 120:1076-1086.
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab. Alimentary Pharmacology and Therapeutics. 2025; 61:1063-1064.
AN EVALUATION OF ENDOSCOPIC HEALING IN PEDIATRIC CROHN’S DISEASE USING MULTIPLE ENDOSCOPIC SCORING METHODS IDENTIFIES SIMILARITIES IN BLOOD AND STOOL BIOMARKERS. Inflammatory Bowel Diseases. 2025; 31:s59-s60.
AN EVALUATION OF ENDOSCOPIC HEALING IN PEDIATRIC CROHN’S DISEASE USING MULTIPLE ENDOSCOPIC SCORING METHODS IDENTIFIES SIMILARITIES IN BLOOD AND STOOL BIOMARKERS. Gastroenterology. 2025; 168:s84-s85.
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease. Clinical and Translational Science. 2025; 18:e70086.
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases. 2024; 30:1678-1685.
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2024; 119:1110-1116.
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases. 2024; 30:S55-S66.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey